Source comparison
GHRP-6 Acetate vs Tesamorelin + Ipamorelin Blend: Research Application Comparison
Primary Mechanism Ghrelin receptor (GHS-R1a) agonist. Direct pituitary stimulation Dual pathway: GHRH receptor (Tesamorelin) + selective GHS (Ipamorelin) Blend provides broader pathway coverage without ghrelin side effects GH Pulse Profile Acute spike: 5–10× b
This comparison does not assign a generated winner or score.
- Primary Mechanism
- Ghrelin receptor (GHS-R1a) agonist. Direct pituitary stimulation
- Dual pathway: GHRH receptor (Tesamorelin) + selective GHS (Ipamorelin)
- Blend provides broader pathway coverage without ghrelin side effects
- GH Pulse Profile
- Acute spike: 5–10× baseline at 30–45 min, returns to baseline within 2 hours
- Sustained elevation: 2–4× baseline over 3–4 hours with dual-component dosing
- Blend better mimics physiological pulsatility for multi-week protocols
- Appetite Effect
- Significant stimulation in 60–70% of subjects via hypothalamic ghrelin pathways
- None. No ghrelin receptor activation with either component
- Critical difference for metabolic and body composition studies
- Cortisol/ACTH Effect
- 10–15% elevation from baseline, transient but measurable
- No cortisol or ACTH stimulation. Ipamorelin is ACTH-neutral
- Blend eliminates stress hormone confounding in metabolic research
- Dosing Frequency
- 2–3× daily (100–300 mcg per dose) required for sustained effect
- Once or twice daily (1–2 mg Tesamorelin + 200–300 mcg Ipamorelin)
- Lower dosing frequency improves protocol compliance and reduces handling errors
- Research Context Fit
- Acute GH response studies, appetite regulation research, ghrelin pathway investigations
- Body composition, fat loss, metabolic health, aging research, lipodystrophy models
- Blend is superior for sustained metabolic outcomes; GHRP-6 for acute pulse research